HealthyRBRAIN-MDMANCT04060108
Stanford Regulating Circuits of the Brain Study - MDMA
An observational study of Healthy, run by Stanford University at 1 site in United States.
Trial summary
This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- MDMA
- How many people
- 22 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Nov 2021to 1 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Healthy participants ages 18-55 years who have had at least two prior exposures to MDMA
Who may be able to join
- Ages 18-55
- Able to swallow capsules
- All genders and ethno-racial categories
- Able and willing to enroll and provide written informed consent.
- Able to comply with study procedures.
- 2+ prior uses of MDMA when aged 18 years or older and have reported no serious adverse reactions from MDMA or ecstasy.
Show all 12Show fewer
- Non-nicotine user, defined as no primary nicotine exposure for last six months.
- Agree to not use caffeine for 12 hours before and 10 hours after drug administration.
- Not using any medication or substance that might increase the risk of participation and/or interact with MDMA (i.e., serotonergic agents, antidepressants, opiates, any drugs with known interactions with Monoamine Oxidase Inhibitors).
- Must agree to inform the investigators within 48 hours of any changes in medical conditions or procedures.
- If of childbearing potential, must have a negative pregnancy test at study entry and prior to each drug session and must agree to use adequate birth control through 10 days after the last drug session. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones.
- Able to receive an MRI.
Who cannot join
- Have current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator.
- Current psychiatric, mood, anxiety, eating or psychotic disorder assessed at screening with the MINI and medical history.
- Current use of any psychotropic medication (a wash-out period of 5 half-lives will be required prior to drug visits followed by a 1-week stabilization period, if the participant reports recently discontinuing a psychotropic medication).
- Have used Ecstasy (material represented as containing MDMA) within 6 months of the first study dose; or have previously participated in a MAPS-sponsored MDMA clinical trial.
- Positive for drug, or alcohol abuse disorders as assessed through DAST, CUDIT-R, Fagerstrom and AUDIT measures.
- Positive test on urine drug screen for illicit and/or drugs of abuse at screening and prior to study drug administration.
Show all 25Show fewer
- Concurrent use of any medication or substance that might increase the risk of participation and/or interact with MDMA (i.e., serotonergic agents, antidepressants, opiates, any drugs with known interactions with Monoamine Oxidase Inhibitors).
- Unable or unwilling to agree to refrain from using any psychoactive substances (i.e., cannabis), supplements (i.e., St. John's Wort, SAMe, 5HTP) and nonprescription medications (i.e., dextromethorphan) starting 1-week prior to study start and for duration of study.
- Current use of any opioids, including codeine, hydrocodone, and morphine.
- Have an exclusionary metal device (e.g., presence of metallic device or dental braces, which are contraindications for MRI) as determined by the discretion of the Clinical Investigator.
- BMI outside of healthy range (18-30)
- Inability to speak, read or understand English at a 5th grade level or severe hearing impairment.
- Plan to move out of the area during the study period (given repeated testing sessions)
- Individuals who are pregnant or nursing.
- Schizophrenia in a first degree relative.
- Direct physical access to or routinely handling of addicting drugs in the regular course of work duties.
- Allergy or hypersensitivity to MDMA
- Renal/hepatic impairment (assessed via laboratory tests during initial screening appointment)
- Hypertension (Hypertension, Stage 1 as defined by a systolic blood pressure >140 mmHg or diastolic blood pressure > 90 mmHg on two of three measurements at least 15 minutes apart at initial screening appointment; systolic blood pressure >155 mmHg or diastolic blood pressure >99 mmHg on two of three measurements at least 15 minutes apart during drug administration visits)
- Heart rate <50bpm or >150bpm assessed at initial screening visit (PI discretion for bradycardia)
- Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia (assessed via EKG at initial screening appointment)
- Have a marked Baseline prolongation of QT/QTc interval e.g., repeated demonstration of a QTc interval >450 milliseconds (ms) in males and >460 ms in females. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for 5 or more years.
- Have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded). Note: if participants present with a history of glaucoma, enrollment would be allowed only with the approval of their ophthalmologist.
- Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- Have history of hyponatremia or hyperthermia
Trial locations and contacts
1 site in 1 country.
United States1 site
Stanford Psychiatry and Behavioral Sciences Department
Palo Alto, California, 94305
About this study
Official title: Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits - MDMA
This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA.
Read the detailed description
The investigators will assess the effect of acute MDMA modulation on the functioning of human brain circuits. Brain circuits will be assessed using functional magnetic resonance imaging.
Participants will include volunteers who report more than two prior uses of MDMA (also known as Ecstasy), when they were 18 years or older.
The investigators will recruit individuals who have previously tried MDMA rather than those who are MDMA-naïve.
Participants will receive an oral dose of MDMA (80mg and 120mg) and placebo (saline) at 3 separate study sessions. Following established procedures, these three sessions will be randomized in a blinded protocol in order to limit expectancy effects.
Throughout each session, participants will be monitored. Functional imaging will commence after the drug has reached peak levels, following previously established time courses for MDMA administered orally. Participants will also be monitored after the functional imaging session. Secondary effects of MDMA on behavior and self-reported experience will be assessed.
In the assessment of the acute effects of MDMA, the investigators will take into account the cumulative effects of prior drug exposure.
- Conditions
- Healthy
- Being tested
- MDMA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MDMADrug
Also called 3,4-Methyl enedioxy methamphetamine, ecstasy
80mg, 120mg, Placebo
| Study group | Role | What they receive |
|---|---|---|
| MDMA Within Subject Cross-over | Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions. Receives: Drug: MDMA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Facial Expressions of Emotion Task (FEET, nonconscious and conscious) evoked functional activity and connectivity
For the non-conscious task, participants are shown a series of faces, presented in pairs. The first face in each pair is presented for only a fraction of a second and may be hard to see. Participants press a button every time they see a face. For the conscious task, participants do the same thing same but with a new set of faces.
Measured: up to 2 hours after the administration of MDMA or Placebo
Secondary outcomes (22)
Resting-state functional activity and connectivity
Participants will be instructed to stare at a white cross on a black background. During this time, their eyes will be monitored using an eye-tracker by the study coordinator to ensure that the participant is not asleep. Four separate 5-min runs of resting state data will be acquired, two with a posterior-anterior phase encoding direction and the other two with a posterior-anterior direction.
Measured: up to 2 hours after the administration of MDMA or Placebo
MID evoked functional activity and connectivity
Participants watch the screen and see a cue in the form of a circle or square, either of which can be empty or dashed, wait a delay of a varied amount of time, and then seen the target (a white triangle), which they are instructed to respond to with a button press as quickly as possible. The participant is instructed to attempt to press a button while the target is on the screen to either win money or avoid losing money. A feedback slide is presented after each trial to inform the participant whether they were successful on that trial, and the resulting gain or loss of money.
Measured: up to 2 hours after the administration of MDMA or Placebo
Go-No-Go evoked functional activity and connectivity
'Go' trials (the word "press" in GREEN) require participants to respond as quickly as possible, while the 'NoGo' trials ("press" in RED) require participants to withhold responses.
Measured: up to 2 hours after the administration of MDMA or Placebo
Behavioral responses on the WebNeuro computerized test battery assessing cognitive capacity
Accuracy data are quantified as number of errors and lower values indicate better performance. The results across all the individual tests are aggregated to a single report that details function as compared to a normative database.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 21-item Depression, Anxiety and Stress Scale (DASS)
Responses are quantified on a 4-point scale and summed for total DASS score and for each Depression, Anxiety and Subscale score. Higher scores indicate more severe symptoms of depression, anxiety and stress.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 29-item Rotter's Locus of Control (RLoC)
Responses are quantified as a summed score from 0 to 23 and determine the degree to which a person perceives an outcome as being contingent on their own actions or those of external forces. Higher scores indicate greater levels of external locus of control.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 15-item Mini Brief Risk-Resilience Index for Screening (BRISC)
Responses are quantified on a 5-point Likert scale and is a measure of emotional self-regulation. Scores measure three core domains: negativity bias, emotional resilience, and social skills. Higher scores indicate higher functioning and better coping.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 14-item Snaith-Hamilton Please Scale (SHAPS)
Responses are quantified on a 4-point scale and measures anhedonia, the inability to experience pleasure. Scores measure domains of social interaction, food and drink, sensory experience, and interest/pastimes. An "abnormal" score is defined as 3 or more.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 24-item Dimensional Apathy Scale (DAS)
Responses are quantified on a 4-point scale and measure demotivation in three domains: executive apathy, emotional apathy, and initiation apathy. Higher scores indicate higher apathy level.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 18-item Motivation and Pleasure Scale Self-Report (MAP-SR)
Responses are quantified on a 5-point Likert scale and assesses an individual's motivation and pleasure. Total scores range from 0-72 and higher scores indicate greater motivation and pleasure during everyday activities.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 17-item Dimensional Anhedonia Rating Scale (DARS)
Responses are summed on a 5-point scale. Scores assess interest, motivation, effort, and consummatory pleasure across four domains: hobbies, food/drink, social activities, and sensory experiences. Lower scores represent a higher level of anhedonia.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 94-item 5-Dimensional Altered States of Consciousness Rating Scale (DASC)
Responses are recorded on a sliding scale with one side reading 'No, not more than usually' and the opposite reading 'Yes, much more than usually'. More agreeance to the statements represents that the individual is experiencing higher levels of altered states of consciousness.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 23-item Social Reward Questionnaire (SRQ)
Responses are averaged on a 7-point Likert scale in relation to the six subscales. Scores assess individual difference in the value of different social rewards. The six subscales of social reward that the questionnaire measures are admiration, negative social potency, passivity, prosocial interactions, sexual reward, and sociability.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-administered computerized task assessed by Multifaceted Empathy Test (MET)
Responses are recorded on a computer-based program. This task utilizes photographic stimuli for measuring both cognitive and emotional empathy.
Measured: up to 5 hours after the administration of MDMA or Placebo
Level of subjectively experienced mood and feelings as assessed by rating scale
Responses will be quantified by intervals of 10 on a scale of 1 to 100.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 23-item Clinician Administered Dissociative States Scale (CADSS)
Responses are summed on a 5-point scale in rating one's agreeance to the dissociative statements as 'not at all' to 'extreme'. Scores assess individual's dissociative state. A higher score represents more dissociation.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by a clinician on the 18-item Brief Psychiatric Rating Scale (BPRS)
Responses are summed on a 7-point scale in rating one's severity to the statements as 'not assessed' to 'extremely severe'. Scores assess psychiatric symptoms like anxiety, depression, and psychoses. A higher score means the individual is presenting more extreme symptoms.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Participants rate acceptance-related experiences and avoidance-related experiences using a visual analog scale from 0-100, with 0 indicating "No, not at all" and 100 indicating "Yes, extremely or absolutely".
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the MID Cue Rating
Survey created for the study where participants are asked to rate the stimulus presented during the MID task on a scale from -5 to 5, with -5 indicating that they disliked it very much, 0 indicating a neutral rating, and 5 indicating that they liked it very much.
Measured: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the Face Likability Rating
Survey created for the study where participants are asked to rate the faces presented during the FEET task on a scale from 0 to 100, where 0 represents the most negative reaction, 50 represents a neutral reaction, and 100 represents the most positive reaction to the face.
Measured: up to 5 hours after the administration of MDMA or Placebo
Steroid hormone assay via saliva collection
At 6 different time points throughout drug administration visits the participant chews on a cotton swab for 30 seconds to collect saliva. A steroid hormone assay is conducted to collect data on cortisol, testosterone, progesterone, and estradiol levels.
Measured: up to 5 hours after the administration of MDMA or Placebo
Qualitative free responses
Subjects will be prompted to report their drug experience throughout the drug visit.
Measured: up to 5 hours after the administration of MDMA or Placebo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2019
- Study start2 Nov 2021
- Primary completion1 Jan 2024
- Study completion1 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA), Resilient Pharmaceuticals
- Responsible party
- Principal investigator, Leanne Williams, Stanford University
- Investigators
- Leanne M Williams, PhD, Principal investigator, Stanford PI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04060108
- Sponsor's protocol ID
- 52244
- Other IDs
- 1P50DA042012-01A1
- Acronym
- RBRAIN-MDMA
- Status last verified
- Dec 2025
- First submitted
- 6 Aug 2019
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhang X, Hack LM, Bertrand C, Hilton R, Gray NJ, Boyar L, Laudie J, Heifets BD, Suppes T, van Roessel PJ, Rodriguez CI, Deisseroth K, Knutson B, Williams LM. Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial. JAMA Netw Open. 2025 Apr 1;8(4):e257803. doi: 10.1001/jamanetworkopen.2025.7803.
PubMed 40305021
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits - MDMA
- ClinicalTrials.gov ID
- NCT04060108
- Acronym / sponsor ID
- RBRAIN-MDMA / 52244
- Conditions
- Healthy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA), Resilient Pharmaceuticals
- Study start
- 2 Nov 2021 (actual)
- Primary completion
- 1 Jan 2024 (actual)
- Study completion
- 1 Jan 2024 (actual)
- First posted
- 16 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA.
Detailed description
The investigators will assess the effect of acute MDMA modulation on the functioning of human brain circuits. Brain circuits will be assessed using functional magnetic resonance imaging.
Participants will include volunteers who report more than two prior uses of MDMA (also known as Ecstasy), when they were 18 years or older.
The investigators will recruit individuals who have previously tried MDMA rather than those who are MDMA-naïve.
Participants will receive an oral dose of MDMA (80mg and 120mg) and placebo (saline) at 3 separate study sessions. Following established procedures, these three sessions will be randomized in a blinded protocol in order to limit expectancy effects.
Throughout each session, participants will be monitored. Functional imaging will commence after the drug has reached peak levels, following previously established time courses for MDMA administered orally. Participants will also be monitored after the functional imaging session. Secondary effects of MDMA on behavior and self-reported experience will be assessed.
In the assessment of the acute effects of MDMA, the investigators will take into account the cumulative effects of prior drug exposure.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MDMA Within Subject Cross-over | – | Drug: MDMAParticipants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy participants ages 18-55 years who have had at least two prior exposures to MDMA
Key inclusion criteria (12 listed)
- Ages 18-55
- Able to swallow capsules
- All genders and ethno-racial categories
- Able and willing to enroll and provide written informed consent.
- Able to comply with study procedures.
Key exclusion criteria (25 listed)
- Have current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator.
- Current psychiatric, mood, anxiety, eating or psychotic disorder assessed at screening with the MINI and medical history.
- Current use of any psychotropic medication (a wash-out period of 5 half-lives will be required prior to drug visits followed by a 1-week stabilization period, if the participant reports recently discontinuing a psychotropic medication).
- Have used Ecstasy (material represented as containing MDMA) within 6 months of the first study dose; or have previously participated in a MAPS-sponsored MDMA clinical trial.
- Positive for drug, or alcohol abuse disorders as assessed through DAST, CUDIT-R, Fagerstrom and AUDIT measures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MDMAAlso: 3,4-Methyl enedioxy methamphetamine, ecstasy80mg, 120mg, Placebo | Drug | MDMA Within Subject Cross-over |
Primary outcome
Facial Expressions of Emotion Task (FEET, nonconscious and conscious) evoked functional activity and connectivity
Time frame: up to 2 hours after the administration of MDMA or Placebo
For the non-conscious task, participants are shown a series of faces, presented in pairs. The first face in each pair is presented for only a fraction of a second and may be hard to see. Participants press a button every time they see a face. For the conscious task, participants do the same thing same but with a new set of faces.
22 secondary outcomes
Resting-state functional activity and connectivity
Time frame: up to 2 hours after the administration of MDMA or Placebo
MID evoked functional activity and connectivity
Time frame: up to 2 hours after the administration of MDMA or Placebo
Go-No-Go evoked functional activity and connectivity
Time frame: up to 2 hours after the administration of MDMA or Placebo
Behavioral responses on the WebNeuro computerized test battery assessing cognitive capacity
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 21-item Depression, Anxiety and Stress Scale (DASS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 29-item Rotter's Locus of Control (RLoC)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 15-item Mini Brief Risk-Resilience Index for Screening (BRISC)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 14-item Snaith-Hamilton Please Scale (SHAPS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 24-item Dimensional Apathy Scale (DAS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 18-item Motivation and Pleasure Scale Self-Report (MAP-SR)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 17-item Dimensional Anhedonia Rating Scale (DARS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 94-item 5-Dimensional Altered States of Consciousness Rating Scale (DASC)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 23-item Social Reward Questionnaire (SRQ)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-administered computerized task assessed by Multifaceted Empathy Test (MET)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Level of subjectively experienced mood and feelings as assessed by rating scale
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the 23-item Clinician Administered Dissociative States Scale (CADSS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by a clinician on the 18-item Brief Psychiatric Rating Scale (BPRS)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the MID Cue Rating
Time frame: up to 5 hours after the administration of MDMA or Placebo
Self-reported responses as assessed by the Face Likability Rating
Time frame: up to 5 hours after the administration of MDMA or Placebo
Steroid hormone assay via saliva collection
Time frame: up to 5 hours after the administration of MDMA or Placebo
Qualitative free responses
Time frame: up to 5 hours after the administration of MDMA or Placebo
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Results publication: PubMed 40305021Zhang X, Hack LM, Bertrand C, Hilton R, Gray NJ, Boyar L, Laudie J, Heifets BD, Suppes T, van Roessel PJ, Rodriguez CI, Deisseroth K, Knutson B, Williams LM. Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial. JAMA Netw Open. 2025 Apr 1;8(4):e257803. doi: 10.1001/jamanetworkopen.2025.7803.
- Individual participant dataSharing planned: No
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leanne M Williams, PhD principal investigator
Stanford PI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Facial Expressions of Emotion Task (FEET, nonconscious and conscious) evoked functional activity and connectivity (time frame: up to 2 hours after the administration of MDMA or Placebo). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04060108, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.